How will B-cell-receptor-targeted therapies change future CLL therapy? - sprookjes - yvandenbroek - TriplyDB

How will B-cell-receptor-targeted therapies change future CLL therapy?

How will B-cell-receptor-targeted therapies change future CLL therapy?

http://www.wikidata.org/entity/Q27024187

about

The tumor microenvironment shapes hallmarks of mature B-cell malignancies.Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review The structural basis for cancer treatment decisions.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation.Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival Ibrutinib: a paradigm shift in management of CLL.Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?Recent advances in therapy of chronic lymphocytic leukaemia.Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies.Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.Specific cytotoxic T-cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells.The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.

P2860

Q27687567-E6626B3F-EDDB-42D9-9F36-69871C8C457C Q33416524-80044138-C3FC-4899-A77E-3D674617FA10 Q33424543-BAFC9082-9A30-44F0-B354-87BD17BAEBEA Q34348572-AE72A404-0499-430A-8770-D277E482A3CB Q34365654-F215A3C5-9D9A-4784-9282-281B2A3D8883 Q34625543-ACBE4285-39B0-401D-897F-CA6FD51A540E Q34769213-98601D83-AF40-4AB5-BB2E-D9E0DACA8C21 Q35775881-466237E9-BD69-47C8-9A9D-9FC58D5CC923 Q35852684-34021885-E3D4-4E20-8794-33FC2003F941 Q36036102-ADF2D2E0-7163-47A8-8CCB-45E9A1A8D2C1 Q36118111-8628918E-BFAC-487A-86BA-AD0AB8E65EDE Q36274292-BEC83473-30EB-4D53-A5A6-C3397A6D4D76 Q36561705-1767FE81-21EA-4931-B85D-3B8C6C3A7D33 Q36739295-AE9B1116-3EDF-4AED-B59B-9C4A4717478F Q36777093-9041C107-C2FC-41D6-9B4D-1892E23E6A35 Q38340201-B11584AA-1363-4A3B-AA37-BAC4E09D4705 Q38862525-E7268D06-D47B-48EC-BF5C-AB32226606A6 Q38984735-131A4535-F2DB-4CBF-8B20-370E53C31F3D Q47300115-2919D40E-9DDE-48BB-B913-7417B5192F97 Q48307279-5C67965D-4E45-47F4-A08C-F0CA56B83A05 Q50654687-36BD0401-4C17-4235-97D1-08A5E6134C40 Q51150640-79930640-7CB9-4C06-948D-AD06301F8EAA

P2860

How will B-cell-receptor-targeted therapies change future CLL therapy?

http://www.wikidata.org/entity/Q27024187

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

How will B-cell-receptor-targeted therapies change future CLL therapy?

@ast

How will B-cell-receptor-targeted therapies change future CLL therapy?

@en

How will B-cell-receptor-targeted therapies change future CLL therapy?

@nl

type

label

How will B-cell-receptor-targeted therapies change future CLL therapy?

@ast

How will B-cell-receptor-targeted therapies change future CLL therapy?

@en

How will B-cell-receptor-targeted therapies change future CLL therapy?

@nl

prefLabel

How will B-cell-receptor-targeted therapies change future CLL therapy?

@ast

How will B-cell-receptor-targeted therapies change future CLL therapy?

@en

How will B-cell-receptor-targeted therapies change future CLL therapy?

@nl

P1433

Q27024187-C6EEE15C-3823-4C26-A586-25BE6EA275A2

P1476

Q27024187-2E49D29D-DC50-4D9A-9FE3-D0BE8EF4AF34

P2093

Q27024187-43E2C7FA-5D88-4F06-A67E-8C735797A61F

Q27024187-AFB311DA-CB1A-4043-93A9-F8C12E7F8221

P2860

Q27024187-068A4C7F-C8CC-4D49-AB3A-94735D1D1BF0

Q27024187-0953749E-2BE6-40FF-919E-A99174CCAF3F

Q27024187-0E7CA653-943D-475B-89C5-2361C699AFEA

Q27024187-21A8FE4C-EED4-4252-8EB0-CD4781D80E13

Q27024187-22937436-7E4E-41EE-A5BA-DCC4BF15C70E

Q27024187-293DC62A-65D7-453E-851C-371EA11E50F6

Q27024187-39B58841-1F42-472C-9630-1A101DD6CF68

Q27024187-39CD0676-3926-4565-B45D-7FEA8237AA76

Q27024187-3D505B8F-9F28-4C5B-9CE5-1FC50B60385F

Q27024187-3E00AB19-9D01-4B1C-8E35-DC2C752CD316

P304

Q27024187-96FC6413-4972-4597-9823-B6B70F7415A6

P31

Q27024187-7648A762-F39D-4223-8B17-C30FB2305C32

P3181

Q27024187-8C835DAB-97E4-4C31-8BFE-78A4640A2C5F

P356

Q27024187-1441BDD5-78B6-4351-8E0D-9F94EDC129A8

P407

Q27024187-859CFAB1-1FD0-4BD4-937B-305D32CBB3BA

P433

Q27024187-D4D6B56A-2082-465F-9856-888723C97F27

P478

Q27024187-6AF8C04E-9A1F-48E8-A8C9-795850A02BC7

P577

Q27024187-A8C8EB9B-BA5B-4EB0-BC6F-A33702C29CD2

P5875

Q27024187-F56F6ABC-72DA-48FF-82D1-748675A8E8E8

P698

Q27024187-E4E07E27-D4FC-410D-A206-DA5E44F2F0D0

P932

Q27024187-61E67718-2CE8-4371-A759-8BA19E1F1A82

P3181

P356

BLOOD-2013-09-453092

P1433

P1476

How will B-cell-receptor-targeted therapies change future CLL therapy?

@en

P2093

J. A. Jones

http://www.w3.org/2001/XMLSchema#string

J. C. Byrd

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

P304

1455-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1116041

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2013-09-453092

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259606805

http://www.w3.org/2001/XMLSchema#string

P698

24394667

http://www.w3.org/2001/XMLSchema#string

P932

3945859

http://www.w3.org/2001/XMLSchema#string